Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid

Vaccine

Volumn 18, Issue 5-6, 1999, Pages 531-539

  Keitel, W A ^a   Kester, K E ^b   Atmar, R L ^a   White Jr, A C ^a   Bond, N H ^a   Holland, C A ^b   Krzych, U ^b   Palmer, D R ^b   Egan, A ^c   Diggs, C ^d   Ballou, W R ^b   Hall, B F ^c   Kaslow, D ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

Author keywords

Malaria vaccines; Merozoite surface protein; Plasmodium falciparum

Indexed keywords

MALARIA VACCINE; MEMBRANE PROTEIN; RECOMBINANT VACCINE; TETANUS TOXOID;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALARIA FALCIPARUM; MALE; MEROZOITE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RASH; SKIN TEST;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMODIUM FALCIPARUM; SKIN TESTS; T-LYMPHOCYTES, HELPER-INDUCER; TETANUS TOXOID; VACCINES, SYNTHETIC;

EID: 0032866084     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00221-2     Document Type: Article

References (26)

1. Anonymous. Control of Tropical Disease (CTD), Malaria Control; World Health Organization, 1995.
2. Holder A.A. Proteins on the surface of the malaria parasite and cell invasion. Parasitol. 108:1994;5-18.
3. Blackman M.J., Heidrich H.G., Donachie S., McBride J.S., Holder A.A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J. Exp. Med. 172:1990;379-382.
4. Riley E.M., Allen S.J., Wheeler J.G., Blackman M.B., Bennett S., Takacs B., Schonfeld H.J., Holder A.A., Greenwood B.M. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP-1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasitol. Immunol. 14:1992;321-337.
5. Egan A., Morris J., Barnish G., Allen S.J., Greenwood B.M., Kaslow D.C. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen PfMSP-1. J. Infect. Dis. 173:1996;765-769.
6. Holder A.A., Freeman R.R. Immunization against blood-stage rodent malarias using purified parasite antigens. Nature. 294:1981;361-364.
7. Ling I.T., Ogun S.A., Holder A.A. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Parasitol. Immunol. 16:1994;63-67.
8. Kumar S., Yadava A., Keister D.B., Tian J.H., Ohl M., Perdue-Greenfield K.A., Miller L.H., Kaslow D.C. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol. Med. 1:1995;332.
9. Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149:1992;717-721.
10. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:1989;2237-2242.
11. Kaslow D.C., Hui G., Kumar S. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP-119) variants secreted from Saccharomyces cerevisiae. Mol. Biochem. Parasitol. 63:1994;283-289.
12. Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149:1992;717-721.
13. Eisel U., Jarausch W., Goretzki K., Henschen A., Engels J., Weller U., Hudel M., Haberman E., Niemann H. Tetanus Toxin: primary structure, expression in E. coli and homology with botulinum toxins. Embo. J. 6:1986;2495-2502.
14. Glenn G.M., Rao M., Richards R.L., Matyas G.R. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. Immunol. Lett. 47:1995;73-78.
15. Wirtz R.A., Ballou W.R., Schneider I., Chedid I., Gross J., Young J.F., Hollingdale M., Diggs C.L., Hockmeyer W.T. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Exp. Parasitol. 63:1987;166-172.
16. Procedure Manual, IBT Reference Laboratory, Lenexa, KS.
17. Nalebuff D.J., Fadal R.G., May B.C. A comparative study of the diagnostic characteristics of the modified RAST and Pharmacia CAP System. Otolaryngol. Head and Neck Surg. 109:1993;601-605.
18. Leary H.L., Halsey J.F. An assay to measure antigen-specific immune complexes in food-allergy patients. J. Allergy. Clin. Immunol. 74:1984;190-195.
19. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., Marchand M., Ballu W.R., Cohen J.D. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum Malaria. N. Engl. J. Med. 336:1997;86-91.
20. Schwartz L.B., Metcalf D.D., Miller J., Eerl H. Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 316:1987;1622-1626.
21. Pattaroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Tascon R., Romero P., Franco A., Murillo L.A., Ponton G. A synthetic vaccine protects humans against challenge with asexual blood stages of P. falciparum. Nature. 332:1988;356-361.
22. Noya O., Berti Y.G., deNoya B.A., Borges R., Zerpa N. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170:1994;396-402.
23. Nosten F., Luxenburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E.H., Chongsuphajaisiddhi T., Gordon D.M., White N.J., Sadoff J.C., Heppner D.G. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet. 348:1996;701-707.
24. Ballou W.R., Hoffman S.L., Sherwood J.A., Hollingdale M.R., Neva F.A., Hockmeyer W.T. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 6:1987;1277-1281.
25. Heppner D.G., Gordon D.M., Gross M., Welde B., Leitner W., Krzych U. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174:1996;361-366.
26. Good M.F. Immunological responses from nonexposed donors to malaria antigens: implications for immunity and pathology. Immunol. Lett. 41:(2-3):1994;123-125.